| Macular edema due to diabetes mellitus
Eylea HD vs Vabysmo
Side-by-side clinical, coverage, and cost comparison for macular edema due to diabetes mellitus.Deep comparison between: Eylea Hd vs Vabysmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVabysmo has a higher rate of injection site reactions vs Eylea Hd based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vabysmo but not Eylea Hd, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eylea Hd
Vabysmo
At A Glance
Intravitreal injection
Every 8-16 weeks
VEGF-A/PlGF inhibitor
Intravitreal injection
Every 4-8 weeks
VEGF-A and Ang-2 inhibitor
Indications
- Age related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Macular retinal edema
Dosing
Age related macular degeneration, Macular edema due to diabetes mellitus 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 16 weeks (+/- 1 week); extended dosing once every 20 weeks (+/- 1 week) may be considered after 1 year of successful response.
Diabetic Retinopathy 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 12 weeks (+/- 1 week).
Retinal Vein Occlusion 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 to 5 doses, then once every 8 weeks (+/- 1 week).
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection every 4 weeks for first 4 doses, followed by dosing every 8, 12, or 16 weeks based on OCT and visual acuity evaluations; some patients may need every 4-week dosing.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 4 weeks for at least 4-6 doses, then interval adjusted to every 4-8 weeks based on CST and visual acuity evaluations.
Macular retinal edema 6 mg (0.05 mL) by intravitreal injection every 4 weeks.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to aflibercept or any excipient in EYLEA HD
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to faricimab or any excipient in VABYSMO
Adverse Reactions
Most common (>=3%) Cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment, vitreous floaters
Serious Endophthalmitis, retinal detachments, retinal vasculitis with or without occlusion, increase in intraocular pressure, thromboembolic events
Postmarketing Retinal vasculitis, occlusive retinal vasculitis, scleritis
Most common (>=1%) Conjunctival hemorrhage, cataract, vitreous detachment, vitreous floaters, intraocular pressure increased, eye pain, intraocular inflammation, retinal pigment epithelial tear, eye irritation, lacrimation increased, ocular discomfort
Serious Endophthalmitis, retinal detachment, increase in intraocular pressure, thromboembolic events, retinal vasculitis and/or retinal vascular occlusion
Postmarketing Retinal vasculitis with or without retinal vascular occlusion
Pharmacology
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, inhibiting their binding and activation of VEGFR-1 and VEGFR-2, thereby suppressing neovascularization and vascular permeability in the eye.
Faricimab is a humanized bispecific antibody that inhibits two pathways by binding to VEGF-A and Ang-2; VEGF-A inhibition suppresses endothelial cell proliferation, neovascularization, and vascular permeability, while Ang-2 inhibition promotes vascular stability and desensitizes blood vessels to the effects of VEGF-A.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eylea Hd
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Vabysmo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Eylea Hd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vabysmo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Eylea Hd
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Vabysmo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Eylea HdView full Eylea Hd profile
VabysmoView full Vabysmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.